[1. Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T, Ajarim D, Adra C. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules // PLos One, 2011; 6(11):e27339 10.1371/journal.pone.0027339320862322076152]Search in Google Scholar
[2. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O’Connell P, Tsimelzon A, Medina D. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution // Clin Cancer Res, 2008; 14:370 - 378 ]Search in Google Scholar
[3. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression // J Pathol, 2011; 223: 307 - 317 ]Search in Google Scholar
[4. Bostrom P, Soderstrom M, Vahlberg T, Soderstrom KO, Roberts PJ, Carpen O, Hirsimaki P. MMP-1 expression has an independent prognostic value in breast cancer // BMC Cancer, 2011; 11:348 ]Search in Google Scholar
[5. Buerger H, Otterback F, Simon R, Schafer KL, Poremba C, Diallo R, Brinkschmidt C, Dockhorn- Dworniczak B, Boecker W. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes // J Pathol, 1999; 189: 521 - 526 ]Search in Google Scholar
[6. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina breast cancer study // J Am Med Assoc, 2006; 295: 2492 - 2502 ]Search in Google Scholar
[7. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer // J Natl Cancer Inst, 2009; 101:736 - 750 ]Search in Google Scholar
[8. Farmer P, Bonnefoi H, Becette V, Tubiana- Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis // Oncogene, 2005; 24:4660 - 4671 ]Search in Google Scholar
[9. Gabos Z, Sinha R, Hanson J, Chauhen N, Hugh J, Mackey JR, Abdulkarim B. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breats cancer // J Clin Oncol, 2006; 24(36):5658 - 5663 ]Search in Google Scholar
[10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 // Ann Oncol, 2011; 22(8):1736 - 1747 ]Search in Google Scholar
[11. Guarneri V, Conte PF. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy // The Oncologist, 2009; 14:645 - 656 ]Search in Google Scholar
[12. Huang Y, Nayak S, Jankowitz R, Davidson NE, Oesterreich S. Epigenetics in breast cancer: what’s new? // Breast Cancer Res, 2011; 13:225. ]Search in Google Scholar
[13. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cell and their dynamic equilibrium with non-stem cancer cells via IL6 secretion // Proc Natl Acad Sci USA. 2011; 108(4):1397 - 1402 ]Search in Google Scholar
[14. Kang JH, Song KH, Jeong KC, Kim S, Choi C, Lee CH, Oh SH. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells // BMC Cancer, 2011; 11:334 ]Search in Google Scholar
[15. Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers // Cancer Biol Ther, 2010; 10(10):955 - 960 ]Search in Google Scholar
[16. Natrajan R, Lambros MB, Geyer FC, Marchio C, tan DS, Vatcheva R, Shiu KK, Hungermann D, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Buerger H, Reis-Filho JS. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with luminal phenotype? // Genes Chromosomes Cancer, 2009; 48:351 - 365 ]Search in Google Scholar
[17. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma // Clin Cancer Res, 2004; 10: 5367 - 5374 ]Search in Google Scholar
[18. Nielsen TO, Parker JS, Leung S. Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer // Clin Cancer Res, 2010; 16:5222 - 5232 ]Search in Google Scholar
[19. Nowell PC. The clonal evolution of tumor cell populations // Science, 1976; 194:23 - 28 ]Search in Google Scholar
[20. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes // J Clin Oncol, 2009; 27:1160 - 1167 ]Search in Google Scholar
[21. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conguer // Cancer Invest, 2008; 26:1 - 10 ]Search in Google Scholar
[22. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portreits of human breast tumours // Nature, 2000; 406: 747 - 752 ]Search in Google Scholar
[23. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER2-overexpressing and triple-negative breast cancer // Cancer, 2008; 113(7):1521 - 1526 ]Search in Google Scholar
[24. Place AE, Huh SJ, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment // Breast Cancer Res, 2011; 13:227 ]Search in Google Scholar
[25. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowith JI, He X, Perous CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer // Breast cancer Res, 2010; 12:R68. 10.1186/bcr2635309695420813035]Search in Google Scholar
[26. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells // Nature, 2001; 414:105 - 111 ]Search in Google Scholar
[27. Reyal F, Rouzier R, Depont-Hazelzet B, Bollet MA, Pierga JY, Alran S, Salmon RJ, Fourchotte V, Vincent-Salomon A, Sastre-Garau X, Antoine M, Uzan S, Sigal-Zafrani B, De Rycke Y. The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma // PLoS One, 2011; 6(5):e20297. 10.1371/journal.pone.0020297310505321655258]Search in Google Scholar
[28. Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A, Sheer D. Comparative genomic hybridization of breast tumors stratified by histologic grade reveals new insights into the biological progression of breast cancer // Cancer Res, 1999; 59:1433 - 1463 ]Search in Google Scholar
[29. Rozier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy // Clin Cancer Res, 2005; 11(16):5678 - 5685 ]Search in Google Scholar
[30. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities // Eur J Cancer, 2004; 40:2667 - 2675 ]Search in Google Scholar
[31. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale Al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications // Proc Natl Acad Sci USA, 2001; 98:10869 - 10874 ]Search in Google Scholar
[32. Strehl JD, Wachter DL, Fasching PA, Beckmann MW, Hartmann A. Invasive breast cancer: Recognition of molecular subtypes // Breast Care, 2011; 6:258 - 264 ]Search in Google Scholar
[33. Tan J, Buache E, Chenard MP, Dali-Youcef, Rio MC. Adipocyte is a non-trivial, dynamic partner of breast cancer cells // Int J Dev Biol, 2011; 55:851 - 859 ]Search in Google Scholar
[34. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse // J Clin Oncol, 2010; 28(10):1684 - 1691 ]Search in Google Scholar
[35. Zaha DC, Lazar E. Molecular characterization of apoptosis by the immunohistochemical evaluation of Bcl-2 in breast cancer // Rom J Morphol Embryol, 2012; 53(1): 155 - 160 ]Search in Google Scholar
[36. Wander SA, Zhao D, Slingerland JM. P27: a barometer of signalind deregulation and potential predictor of response to targeted therapies // Clin Cancer Res, 2011; 17(1):12 - 18 ]Search in Google Scholar
[37. Weigelt B, Mackay A, A’Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Breast cancer molecular profiling with single sample predictors: a retrospective analysis // Lancet Oncol, 2010; 11(4):339 - 349 ]Search in Google Scholar
